was defined by anti-HCV antibody seroconversion within a 2-year interval. Stored serum samples were tested for HCV RNA, with viral clearance defined as у2 consecutive negative HCV RNA test results after infection. Ninety-nine cases of HCV infection were identified; 57 had у2 HCV RNA test results after infection. Viral clearance occurred in 24 (42%) cases, with Kaplan-Meier estimated probabilities of 23%, 38%, and 40% at 6, 12, and 24 months, respectively.
broadly representative of acute HCV infection [2] . Progression to chronic HCV infection has generally been defined by the persistence of HCV RNA for at least 6 months [1] ; however, recent evidence suggests that spontaneous viral clearance may extend to 2 years [3] . Consequently, uncertainty remains regarding the rate, time course, and predictors of viral clearance following acute HCV infection.
In Australia, 190% of new HCV infections are attributed to injection drug use, and the estimated incidence of HCV increased from 11,000 cases in 1997 to 16,000 cases in 2001 [4] . The ongoing collection and storage of serum samples obtained from a large cohort of injection drug users (IDUs) attending a primary care clinic in Sydney provided the opportunity to conduct an investigation of the natural history of newly acquired HCV infection. Specific aims were to determine the rate, time course, and predictors of viral clearance.
Subjects, materials, and methods. The Kirketon Road Centre (KRC) is a government-funded, primary health-care facility in central Sydney involved in the prevention and treatment of HIV and other transmissible infections among at-risk youth, sex workers, and IDUs. Clients voluntarily attend for a wide range of clinical services, including testing for bloodborne viruses. At all visits that involve serological testing, demographic, clinical, and risk-behavior data are systematically collected from clients and are entered into a central database. Behavioral data relate to the 12-month period preceding the test or to the period since the previous test, whichever is shorter. Results of serological testing for HIV, hepatitis A virus, hepatitis B virus, and HCV and of liver function tests are recorded in the database. Excess serum from all specimens used for serological testing is routinely stored at Ϫ20ЊC.
A retrospective cohort study design was used to identify all IDUs from the KRC database who had evidence of newly acquired HCV infection, as defined on the basis of HCV antibody seroconversion within a 2-year interval. HCV antibody testing had been performed in a single laboratory, with duplicate testing by use of second-and third-generation EIAs.
For each person identified as having newly acquired HCV infection, all available stored serum samples from the time of the last negative HCV antibody test result were retrieved from storage and were tested retrospectively for the presence of HCV RNA. Quantitation of HCV RNA was performed on all specimens by use of the VERSANT HCV RNA 3.0 Assay (HCV 3.0 bDNA Assay; Bayer Diagnostics). The assay has lower and upper detection limits of and copies/mL, re- 3 7 3.2 ϫ 10 4.0 ϫ 10 spectively. Specimens that yielded a value below the detection limit were tested for HCV RNA by use of nested reverse-transcriptase polymerase chain reaction, as described elsewhere [5] . Validity of retrospective HCV RNA testing was assessed in 22 specimens for which clinical qualitative HCV RNA testing had been conducted at the time of sampling. There was concordance for 13 of The cumulative incidence of viral clearance was estimated by use of the Kaplan-Meier method. Univariate Cox proportional-hazards regression was used to determine predictors of viral clearance. The demographic, behavioral, and clinical factors examined (table 1) were those recorded at the time of the first positive or indeterminate HCV antibody test result. Medical notes were searched for data on acute hepatitis symptoms. Peak alanine aminotransferase (ALT) level and ALT normalization were also examined as potential predictors of viral clearance. Peak ALT level was defined as the highest ALT measurement available within 12 months of the estimated date of HCV infection. ALT normalization was defined as у2 consecutive ALT measurements !40 IU/L after the estimated date of HCV infection.
Because of the possibly reduced sensitivity for the detection of HCV RNA in samples stored for long periods, estimations of viral clearance were also performed for 2 time periods: 1992-1996 and 1997-2002. Statistical analysis was performed by use of SAS (version 8.2; SAS Institute) and STATA (version 8.0; StataCorp) software. All statistical tests were 2-sided; was con-P ! .05 sidered to be statistically significant.
All study subjects had given written consent at the time of registration at KRC for their results to be used for research purposes and had ongoing access to free medical care, including a specialty hepatitis C clinic. Ethical approval for the study was obtained from the South Eastern Sydney Area Health Service Research and Ethics Committee.
Results. A total of 99 IDUs who attended KRC between January 1992 and May 2002 had evidence of newly acquired HCV infection. The median interval between negative and positive HCV antibody test results was 9.2 months (range, 0.6-23.4 months). Fifty-three percent of the IDUs were female, and 12% self-identified as Aboriginal. The median age at first injection drug use was 15 years, and the median age at the estimated date of HCV infection was 22 years. For 71% of IDUs, the main drug injected during the 12 months before the first positive HCV antibody test was heroin, and most of them (64%) were injecting at least daily. Sharing of injection equipment during the 12 months preceding the first positive HCV antibody test result was reported by 63% of IDUs. Only 2% of IDUs were HIV positive. The majority (54%) of IDUs had a history of imprisonment. Symptoms suggestive of acute hepatitis between the last negative and the first positive HCV antibody test result were uncommon, with only 8% of IDUs having documented jaundice. Viral clearance occurred in 42% (24/57) of IDUs. Estimated viral clearance by Kaplan-Meier survival analysis was 23%, 38%, and 40% at 6, 12, and 24 months, respectively (figure 1). Median time to viral clearance was 5.9 months (IQR, 1.4-11.2 months). There were no baseline demographic, clinical, or behavioral factors significantly associated with viral clearance (table 1). IDUs who experienced ALT normalization were more likely to have experienced viral clearance; however, this did not reach significance (odds ratio, 1.90; 95% confidence interval, 0.77-4.65). Estimates of viral clearance at 6, 12, and 24 months were 27%, 42%, and 45% for IDUs who experienced HCV antibody seroconversion in 1992-1996 ( ), compared with n p 30 19%, 34%, and 34% for IDUs who experienced seroconversion in 1997-2002 ( ), with no significant difference in the n p 27 overall time to clearance ( ). P p .30 For 24 of these 57 IDUs, all specimens tested within 1 year of the estimated time of infection were HCV RNA negative. Because of concerns regarding potential false-positive HCV antibody seroconversion, an analysis of IDUs with detectable HCV RNA within 1 year of the estimated time of infection (33/57 IDUs) was performed. This analysis showed that 24% (8/33) of IDUs had viral clearance, with Kaplan-Meier estimates of 6%, 23%, and 26% at 6, 12, and 24 months, respectively ( figure  1 ). There were no significant differences in baseline characteristics or predictors of clearance between IDUs who were and were not HCV RNA positive within 1 year of the estimated time of infection. Discussion. Among a large cohort of IDUs with newly acquired HCV infection, estimates of viral clearance at 2 years were 26%-40%, depending on the criteria used for case inclusion. Although estimated viral clearance rates varied according to the strictness of the case definition, there were no baseline demographic, clinical, or behavioral factors associated with clearance. The vast majority of clearances occurred within the initial 12 months after the estimated time of infection.
The present study has several limitations. We relied on retrospective HCV RNA testing of serum samples stored at Ϫ20ЊC. Storage conditions are known to affect the stability of HCV RNA [6] , and degradation of HCV RNA occurs with freezethaw cycles and storage temperatures below Ϫ70ЊC [7] . A validation based on 22 stored specimens found 95% concordance between the retrospective and concurrent test results, and estimated clearance rates did not differ significantly by time period of the stored specimens. Testing intervals for HCV RNA varied with some wide intervals, potentially leading to overestimation of the time to viral clearance. However, the HCV RNA testing interval was 19 months for only 25% of samples. Viral clearance was defined as у2 consecutive negative HCV RNA test results with a sensitive qualitative HCV RNA assay, but low-level HCV viremia with relapse has been described early during HCV infection [8] . We have reported preliminary findings on HCV reinfection in this cohort [9] . Three of the 33 HCV viremic IDUs at baseline had a further positive HCV RNA test result following a series of negative HCV RNA test results. These IDUs had a minimum of 4 consecutive negative HCV RNA test results over the course of 12, 19, and 26 months, and 2 had a change in HCV genotype, indicating probable cases of reinfection. Detection of clinical symptoms related to acute hepatitis relied on a review of medical notes; therefore, ascertainment bias may explain the absence of an association between the presence of these symptoms and viral clearance.
As in a previous study of a Baltimore cohort of IDUs [10] , we have used a case definition for newly acquired HCV infection based on HCV antibody seroconversion. In contrast, most other studies have monitored subjects with either acute clinical hepatitis [11, 12] or posttransfusion HCV infection [13, 14] . To assess viral clearance, the majority of these studies have required the detection of HCV RNA at baseline. We, therefore, performed analyses of the subgroup of IDUs with confirmed HCV RNA detection occurring near the estimated time of HCV infection. Within this subgroup, viral clearance was estimated at ∼26% at 2 years, higher than the 15% estimate at 3 years from the Baltimore cohort of IDUs [10] but similar to the 25% preliminary estimate from a meta-analysis that we have recently conducted on studies of acute and newly acquired HCV infection [2] . When HCV RNA was not detected at baseline, estimates of viral clearance at 2 years were higher (∼40%).
Predictors of viral clearance in previous studies have included female sex, ethnicity, symptomatic presentation, absence of HIV infection, rapid decline in HCV RNA load, and the strength and pattern of HCV-specific CD4 and CD8 cell responses [15] . The lack of significant demographic predictors of viral clearance within our cohort may relate to the relatively homogenous nature of the study population. The vast majority of IDUs were young, white, HIV antibody negative, and had asymptomatic HCV infection. Furthermore, despite our study population be-ing one of the largest cohorts of subjects with acute or newly acquired HCV infection yet described, the sample size may have limited the detection of significant predictors of viral clearance.
We have demonstrated that at least 1 in 4 IDUs with newly acquired HCV infection undergoes viral clearance. The inclusion of IDUs who had experienced HCV antibody seroconversion, rather than acute clinical hepatitis alone, makes our study more broadly representative of newly acquired HCV infection than most previous studies have been.
